Sofosbuvir and Daclatasvir in Mono- and HIV-coinfected Patients with Recurrent Hepatitis C After Liver Transplant
Lluís Castells
, Jordi Llaneras*, Isabel Campos-Varela‡, Itxarone Bilbao§, Manel Crespo||, Oscar Len||, Francisco Rodríguez-Frías†,¶, Ramon Charco§, Teresa Salcedo**, Juan Ignacio Esteban*,†, Rafael Esteban-Mur*,†
,†,
Corresponding author
* Liver Unit. Department of Internal Medicine, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona. Spain
† Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain
‡ Universidade de Santiago de Compostela (CLINURSID); Department of Internal Medicine, Hospital of Santiago de Compostela. Santiago de Compostela, Spain
§ Liver Transplant Unit, Department of HPB-Surgery and Transplant, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona. Spain
|| Department of Infectious Diseases. Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona. Spain
¶ Biochemistry Laboratory. Hospital Universitari Vall d’Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona. Barcelona, Spain
** Pathology Department. Hospital Universitari Vall d’Hebron. Universitat Autònoma de Barcelona. Spain
Read
1064
Timeswas read the article
365
Total PDF
699
Total HTML
Share statistics
array:24 [ "pii" => "S1665268119303655" "issn" => "16652681" "doi" => "10.5604/16652681.1226819" "estado" => "S300" "fechaPublicacion" => "2017-01-01" "aid" => "70187" "copyright" => "Fundación Clínica Médica Sur, A.C." "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2017;16:86-93" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 103 "formatos" => array:3 [ "EPUB" => 15 "HTML" => 47 "PDF" => 41 ] ] "itemSiguiente" => array:19 [ "pii" => "S1665268119303667" "issn" => "16652681" "doi" => "10.5604/16652681.1226820" "estado" => "S300" "fechaPublicacion" => "2017-01-01" "aid" => "70188" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2017;16:94-106" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 93 "formatos" => array:3 [ "EPUB" => 16 "HTML" => 43 "PDF" => 34 ] ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "Conversion to Mycophenolate Mofetil Monotherapy in Liver Recipients: Calcineurin Inhibitor Levels are Key" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "94" "paginaFinal" => "106" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "f0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 797 "Ancho" => 1381 "Tamanyo" => 83543 ] ] "descripcion" => array:1 [ "en" => "<p id="sp0005" class="elsevierStyleSimplePara elsevierViewall">Description of the study methodology and follow-up: Calcineurin inhibitors were gradually reduced until their total withdrawal during the first four weeks, followed by a 48-week follow-up. Medical evaluations were conducted on the indicated dates and whenever necessary.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Blanca Norero, Carolina A. Serrano, Alberto Sanchez-Fueyo, Ignacio Duarte, Javiera Torres, Mauricio Ocquetau, Francisco Barrera, Marco Arrese, Alejandro Soza, Carlos Benítez" "autores" => array:10 [ 0 => array:2 [ "nombre" => "Blanca" "apellidos" => "Norero" ] 1 => array:2 [ "nombre" => "Carolina A." "apellidos" => "Serrano" ] 2 => array:2 [ "nombre" => "Alberto" "apellidos" => "Sanchez-Fueyo" ] 3 => array:2 [ "nombre" => "Ignacio" "apellidos" => "Duarte" ] 4 => array:2 [ "nombre" => "Javiera" "apellidos" => "Torres" ] 5 => array:2 [ "nombre" => "Mauricio" "apellidos" => "Ocquetau" ] 6 => array:2 [ "nombre" => "Francisco" "apellidos" => "Barrera" ] 7 => array:2 [ "nombre" => "Marco" "apellidos" => "Arrese" ] 8 => array:2 [ "nombre" => "Alejandro" "apellidos" => "Soza" ] 9 => array:2 [ "nombre" => "Carlos" "apellidos" => "Benítez" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119303667?idApp=UINPBA00004N" "url" => "/16652681/0000001600000001/v1_201905311015/S1665268119303667/v1_201905311015/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1665268119303643" "issn" => "16652681" "doi" => "10.5604/16652681.1226818" "estado" => "S300" "fechaPublicacion" => "2017-01-01" "aid" => "70186" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2017;16:77-85" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 133 "formatos" => array:3 [ "EPUB" => 12 "HTML" => 79 "PDF" => 42 ] ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "Differences In Hepatic Expression of Iron, Inflammation and Stress-Related Genes in Patients with Nonalcoholic Steatohepatitis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "77" "paginaFinal" => "85" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "f0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2171 "Ancho" => 1003 "Tamanyo" => 212446 ] ] "descripcion" => array:1 [ "en" => "<p id="sp0010" class="elsevierStyleSimplePara elsevierViewall">Effects of excess iron in patients with NAFLD. Hepatic mRNA expression of: <span class="elsevierStyleBold">A.</span> Inflammatory markers IL-6, IL-1 p, TNFa, NFkB, STAT3, IL-6R and SOCS3 (p values; IL-6: 0.008, IL-1f): 0.06, TNFa: 0.13, NFkB: 0.02, STAT3: 0.97 IL-6R: 0.29, SOCS3: 0.07). <span class="elsevierStyleBold">B.</span> Iron regulatory genes HAMP, HJV, FPN1 BMP6 and TMPRSS6 (p values; HAMP: 0.04, HJV: 0.16, FPN1: 0.51, BMP6: 0.47 and TMPRSS6: 0.19), and <span class="elsevierStyleBold">C.</span> Stress-responsive genes CREBH, HO-1 and HIF-1 a (p values; CREBH: 0.007, HO-1: 0.66 and HIF-1 a: 0.35) in NAFLD + iron patients compared to NAFLD-iron patients. All values are shown as medians and statistical significance (p < 0.05) marked* and p < 0.01 is marked.**</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Priya Handa, Bryan D. Maliken, James E. Nelson, Kelly A. Hennessey, L. Akhila Vemulakonda, Vicki Morgan-Stevenson, Barjinder K. Dhillon, Rohit Gupta, Matthew M. Yeh, Kris V. Kowdley" "autores" => array:10 [ 0 => array:2 [ "nombre" => "Priya" "apellidos" => "Handa" ] 1 => array:2 [ "nombre" => "Bryan D." "apellidos" => "Maliken" ] 2 => array:2 [ "nombre" => "James E." "apellidos" => "Nelson" ] 3 => array:2 [ "nombre" => "Kelly A." "apellidos" => "Hennessey" ] 4 => array:2 [ "nombre" => "L." "apellidos" => "Akhila Vemulakonda" ] 5 => array:2 [ "nombre" => "Vicki" "apellidos" => "Morgan-Stevenson" ] 6 => array:2 [ "nombre" => "Barjinder K." "apellidos" => "Dhillon" ] 7 => array:2 [ "nombre" => "Rohit" "apellidos" => "Gupta" ] 8 => array:2 [ "nombre" => "Matthew M." "apellidos" => "Yeh" ] 9 => array:2 [ "nombre" => "Kris V." "apellidos" => "Kowdley" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119303643?idApp=UINPBA00004N" "url" => "/16652681/0000001600000001/v1_201905311015/S1665268119303643/v1_201905311015/en/main.assets" ] "en" => array:17 [ "idiomaDefecto" => true "titulo" => "Sofosbuvir and Daclatasvir in Mono- and HIV-coinfected Patients with Recurrent Hepatitis C After Liver Transplant" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "86" "paginaFinal" => "93" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Lluís Castells, Jordi Llaneras, Isabel Campos-Varela, Itxarone Bilbao, Manel Crespo, Oscar Len, Francisco Rodríguez-Frías, Ramon Charco, Teresa Salcedo, Juan Ignacio Esteban, Rafael Esteban-Mur" "autores" => array:11 [ 0 => array:4 [ "nombre" => "Lluís" "apellidos" => "Castells" "email" => array:1 [ 0 => "llcastells@vhebron.net" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "aff1" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">†</span>" "identificador" => "aff2" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor1" ] ] ] 1 => array:3 [ "nombre" => "Jordi" "apellidos" => "Llaneras" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "aff1" ] ] ] 2 => array:3 [ "nombre" => "Isabel" "apellidos" => "Campos-Varela" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">‡</span>" "identificador" => "aff3" ] ] ] 3 => array:3 [ "nombre" => "Itxarone" "apellidos" => "Bilbao" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">§</span>" "identificador" => "aff4" ] ] ] 4 => array:3 [ "nombre" => "Manel" "apellidos" => "Crespo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">||</span>" "identificador" => "aff5" ] ] ] 5 => array:3 [ "nombre" => "Oscar" "apellidos" => "Len" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">||</span>" "identificador" => "aff5" ] ] ] 6 => array:3 [ "nombre" => "Francisco" "apellidos" => "Rodríguez-Frías" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">†</span>" "identificador" => "aff2" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¶</span>" "identificador" => "aff6" ] ] ] 7 => array:3 [ "nombre" => "Ramon" "apellidos" => "Charco" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">§</span>" "identificador" => "aff4" ] ] ] 8 => array:3 [ "nombre" => "Teresa" "apellidos" => "Salcedo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">**</span>" "identificador" => "aff7" ] ] ] 9 => array:3 [ "nombre" => "Juan" "apellidos" => "Ignacio Esteban" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "aff1" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">†</span>" "identificador" => "aff2" ] ] ] 10 => array:3 [ "nombre" => "Rafael" "apellidos" => "Esteban-Mur" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "aff1" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">†</span>" "identificador" => "aff2" ] ] ] ] "afiliaciones" => array:7 [ 0 => array:3 [ "entidad" => "Liver Unit. Department of Internal Medicine, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona. Spain" "etiqueta" => "*" "identificador" => "aff1" ] 1 => array:3 [ "entidad" => "Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain" "etiqueta" => "†" "identificador" => "aff2" ] 2 => array:3 [ "entidad" => "Universidade de Santiago de Compostela (CLINURSID); Department of Internal Medicine, Hospital of Santiago de Compostela. Santiago de Compostela, Spain" "etiqueta" => "‡" "identificador" => "aff3" ] 3 => array:3 [ "entidad" => "Liver Transplant Unit, Department of HPB-Surgery and Transplant, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona. Spain" "etiqueta" => "§" "identificador" => "aff4" ] 4 => array:3 [ "entidad" => "Department of Infectious Diseases. Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona. Spain" "etiqueta" => "||" "identificador" => "aff5" ] 5 => array:3 [ "entidad" => "Biochemistry Laboratory. Hospital Universitari Vall d’Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona. Barcelona, Spain" "etiqueta" => "¶" "identificador" => "aff6" ] 6 => array:3 [ "entidad" => "Pathology Department. Hospital Universitari Vall d’Hebron. Universitat Autònoma de Barcelona. Spain" "etiqueta" => "**" "identificador" => "aff7" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "*" "correspondencia" => "Correspondence and reprint request:" ] ] ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "f0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1394 "Ancho" => 2067 "Tamanyo" => 179589 ] ] "descripcion" => array:1 [ "en" => "<p id="sp0005" class="elsevierStyleSimplePara elsevierViewall">Selected laboratory tests and scores over time. Variables are depicted as median and IQR. EOT: end of treatment. FU: follow-up. IQR: intercuarti-le range.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="s0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0035">Introduction</span><p id="p0005" class="elsevierStylePara elsevierViewall">HCV infection is the leading indication for LT in the Western world.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> Among patients with detectable HCV-RNA at the time of transplantation, recurrent infection is universal and leads to cirrhosis 5 years after LT in up to 30% of patients.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,3</span></a> Several studies have shown that HCV eradication after LT improves both graft and patient sur-vival.<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,5</span></a> Hence, it is of primary importance to achieve sustained viral response (SVR) to improve survival after-LT. The availability of interferon free regimens has improved tolerability and rates of SVR, however the new paradigm has not yet been defined.</p><p id="p0010" class="elsevierStylePara elsevierViewall">Until recently, however, SVR rates using Peg-IFN plus RBV based treatment in the LT setting were very limited, ranging between 10 and 35% of patients owing to poor tolera-bility and high rates of premature discontinuation.<span class="elsevierStyleSup">6-8</span> On the other hand, among HIV-coinfected patients, the limited effectiveness of Peg-IFN-based treatment along with the more severe recurrence associated with higher mortality and graft loss rates, have had a negative impact on the willingness of LT programs to enter HIV-infected patients in LT lists.</p><p id="p0015" class="elsevierStylePara elsevierViewall">The advent of interferon-free antiviral regimens with increased efficacy and tolerability offers radically new opportunities to prevent or manage HCV recurrence in both mono- and HIV-coinfected patients and improve long-term survival.</p><p id="p0020" class="elsevierStylePara elsevierViewall">The aim of the current study was to report the efficacy and safety of a 24-week course of sofosbuvir (SOF) and daclatasvir (DCV) without ribavirin in LT HCV monoin-fected and HCV-HIV coinfected LT recipients treated under an international compassionate access program between March and November 2014.</p></span><span id="s0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0040">Material and Methods</span><span id="s0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0045">Patients</span><p id="p0025" class="elsevierStylePara elsevierViewall">Eligible patients were ≥ 18 years, had received a LT, and were also required to have severe, life-threatening HCV recurrence. Treatment regimen consisted on sofosbuvir and daclatasvir without ribavirin for 24 weeks. Sofosbuvir was provided by Gilead Sciencies (Cambridge, UK) and daclatasvir by Bristol-Myers Squibb (Princeton, NJ) as part of an international compassionate use protocol under individual approval.</p><p id="p0030" class="elsevierStylePara elsevierViewall">Patients were approved by the sponsors on a case-by-case basis, following review of submitted information on the patient’s medical history, clinical status and laboratory values. All patients gave written informed consent.</p></span><span id="s0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0050">Study follow-up schedule</span><p id="p0035" class="elsevierStylePara elsevierViewall">There was no planned number of patients. All but one patient received treatment with SOF (400 mg once daily) and DCV (60 mg once daily) without ribavirin for 24 weeks. In one of the six HIV-coinfected patients, DCV dose was reduced to 30 mg once daily, due to concerns on potential drug-drug interactions with ritonavir-containing antiretroviral regimen. Clinical history, physical examination and laboratory tests, including complete blood count (with CD4 T-cell counts, in HIV infected patients), baseline liver function tests and viral loads, were collected weekly during the first month of treatment and monthly thereafter during treatment and 12 weeks after treatment completion. Child-Pugh (CP) and Model for End Stage Liver Disease (MELD) scores were calculated at treatment onset and at weeks 12 and 24 (end of treatment) and at 12 weeks after the end of therapy.</p></span><span id="s0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0055">HCV RNA testing and genotyping</span><p id="p0040" class="elsevierStylePara elsevierViewall">Serum HCV RNA was tested at baseline, during treatment (weeks 1, 2, 3, 4, 8, 12 and 24) and 4 and 12 weeks after treatment completion (SVR4 and SVR12, respectively). HCV RNA levels were tested using a real-time PCR-based assay (Cobas Ampliprep/Cobas TaqMan; Roche Molecular Diagnostics, Barcelona, Spain; lower limit of quantification 15 IU/mL, and lower limit of detection 10 IU/mL). HCV genotyping was determined using a commercially available line probe assay (Inno-LiPA II®; In-nogenetics, Antwerp, Belgium).</p></span><span id="s0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0060">IL28B genotyping</span><p id="p0045" class="elsevierStylePara elsevierViewall">Interleukin IL28B polymorphism rs12979860 (ILB28) of recipients was performed using a real-time PCR with allele-specific Taq-Man probes, as previously de-scribed.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9,10</span></a></p></span><span id="s0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0065">Liver histology</span><p id="p0050" class="elsevierStylePara elsevierViewall">Staging of post-LT HCV recurrence was performed in all patients based on liver biopsy. A single pathologist (TS), blinded to the clinical data, scored biopsy specimens according to the Ishak classification system.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a></p></span><span id="s0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0070">Study assessments</span><p id="p0055" class="elsevierStylePara elsevierViewall">Clinical and laboratory data were prospectively collected for all patients throughout therapy and 12 weeks after the end of therapy. Standard definitions for adverse events (AEs) and serious adverse events (SAEs) were used. Adverse events data were collected in all patients during their treatment period and during their follow-up until the 12th week after the planned end of treatment.</p></span><span id="s0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0075">Statistical analysis</span><p id="p0060" class="elsevierStylePara elsevierViewall">No sample-size calculations were performed, and no inferential statistics or statistical comparisons were planned.</p><p id="p0065" class="elsevierStylePara elsevierViewall">Quantitative variables are presented as medians and interquartile range (IQR), and categorical variables as frequency and percentage. Differences between categorical variables were assessed by χ<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> or Fisher’s exact test. Continuous variables were compared using Mann-Whitney’s test (for umpaired data) or by the <span class="elsevierStyleItalic">t</span>-test or Wilcoxon’s test (for paired data). STATA® v13 (College Station, Texas) was used for all statistical analyses.</p></span></span><span id="s0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0080">Results</span><span id="s0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0085">Baseline characteristics</span><p id="p0070" class="elsevierStylePara elsevierViewall">Baseline characteristics of the 22 patients according to HIV serostatus are summarized in <a class="elsevierStyleCrossRef" href="#t0005">table 1</a>. Six patients (27%) were coinfected by HIV. Overall, most patients were male (86%), had HCV genotype 1b infection (45%), 12 (55%) had failed previous antiviral therapy with PegINF and RBV alone (9 patients) or in combination with a first generation protease inhibitor (3 patients). Median age was 58 years (IQR, 51-68), although the six HIV-HCV coinfected patients were significantly younger (49 <span class="elsevierStyleItalic">vs.</span> 65 years, p = 0.01). HCV monoinfected patients tended to have higher ALT levels (75 <span class="elsevierStyleItalic">vs.</span> 42 IU/mL), higher MELD scores (12 <span class="elsevierStyleItalic">vs</span>. 10), and more advanced fibrosis or cirrhosis (59% <span class="elsevierStyleItalic">vs.</span> 50%) than coinfected patients although the differences were not significant. Albumin levels were higher in monoinfected than in coinfected patients (4.2 <span class="elsevierStyleItalic">vs.</span> 3.4 g/dL, p = 0.001). Immunosuppressant regimen was based on tacrolimus combinations (19 out of 22 patients). The median time from LT to current antiviral therapy was 70 months (IQR, 20-116). At the time of treatment onset, six patients (all HCV-monoinfected) presented decom-pensated cirrhosis with ascites and 2 of them also had hepatic encephalopathy.</p><elsevierMultimedia ident="t0005"></elsevierMultimedia><p id="p0075" class="elsevierStylePara elsevierViewall">All six coinfected patients were under antiretroviral therapy (ART) and had undetectable HIV-RNA levels (< 20 IU/mL) at baseline and remained undetectable throughout the treatment in all patients. Median CD4 and CD8 at baseline were 210 (IQR, 150-400) and 565 (IQR, 450-640) cells/mm<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a>, respectively.</p></span><span id="s0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0090">Efficacy</span><p id="p0080" class="elsevierStylePara elsevierViewall">In the current study, all 22 patients achieved an SVR 12 weeks after end of treatment regardless of HIV status. As shown in <a class="elsevierStyleCrossRef" href="#t0010">table 2</a>, treatment resulted in rapid suppression of circulating virus with a median decrease in HCV-RNA of 3.3 log10 IU/mL at one week (IQR, 2.5-4.1). At week 4, 11 of the 22 patients had HCV-RNA below the limit of quantification (< 15 IU/mL) and at week 8 all but one patient had undetectable HCV-RNA (< 10 IU/mL).</p><elsevierMultimedia ident="t0010"></elsevierMultimedia></span><span id="s0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0095">Liver function</span><p id="p0085" class="elsevierStylePara elsevierViewall">Overall, liver function tests improved significantly over time. Levels of bilirubin, albumin, INR and MELD are shown in <a class="elsevierStyleCrossRef" href="#f0005">Figure 1</a>. Median serum total bilirubin levels decreased significantly from 1.2 mg/dL (0.8-1.9) at baseline to 0.7 mg/dL (p = 0.003) at 12 weeks after end of treatment. Albumin levels increased from 3.6 g/dL to 4 g/dL (P = 0.02). Platelets values increased from 84 to 118 x 10<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a>/ mL (p = 0.03). Improvement in MELD score (decreased from 11 to 10 from baseline to follow-up week 12, p = 0.04) was mostly accounted for by a decrease in bilirrubin levels while improvement in Child-Pugh scores (decreased from 6 to 5, p = 0.003) was mainly due to an increase in albumin levels. No change in international normalized ratio (INR) or creatinine was observed.</p><elsevierMultimedia ident="f0005"></elsevierMultimedia><p id="p0090" class="elsevierStylePara elsevierViewall">At the end of therapy, ascites had resolved in four of the six patients with decompensated cirrhosis at baseline.</p></span><span id="s0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0100">Safety and clinical complications</span><p id="p0095" class="elsevierStylePara elsevierViewall">Overall, seven episodes of clinical complications requiring hospitalization occurred in six patients during treatment. Only one episode of atrioventricular blockade, in a patient receiving amiodarone, was considered related to antiviral therapy. The other episodes were, immune thrombocytopenia (n = 1) which resolved with steroid therapy; tuberculous pleuritis (n = 1), cholangitis due to biliary stricture corrected with stenting (n = 1), post-transplant lymphoproliferative disease (n = 1) and recurrent hepatic encephalopathy with refractory ascites (n = 1). All of them were resolved and didn’t require stopping treatment. After the end of treatment and during follow-up, 2 patients presented biopsy proven mild acute rejection, 2 and 4 weeks after the end of therapy, and both episodes were managed with adjustment of inmunosu-pression therapy.</p><p id="p0100" class="elsevierStylePara elsevierViewall">There was no evidence of treatment associated haema-tological or cutaneous toxicity. Two patients required minor tacrolimus and everolimus dose modification during therapy. During treatment, there were no significant changes either in CD4 or CD8 count in HIV coinfected patients. None of the patients required the use of colony-stimulating agents, erythropoiesis-stimulating agents or blood transfusions.</p><p id="p0105" class="elsevierStylePara elsevierViewall">Although there were no deaths during treatment or immediate follow-up, two patients died (four and eight months after end of therapy) due to complications of end-stage liver disease (due to hepatorenal syndrome and upper gastrointestinal bleeding from ruptured esophageal varices, respectively), despite viral eradication.</p></span></span><span id="s0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0105">Discussion</span><p id="p0110" class="elsevierStylePara elsevierViewall">In the current report, a 24-week course of SOF plus DCV successfully eradicated HCV infection in 22 patients with severe HCV recurrence after LT, including patients with cholestatic hepatitis or decom-pensated cirrhosis, irrespective of HIV status.</p><p id="p0115" class="elsevierStylePara elsevierViewall">HCV recurrence has long been recognized as a major cause of patient and graft loss among HCV-infected liver transplant recipients and limitations in treatment options have represented a major drawback in the transplant set-ting.<span class="elsevierStyleSup">1-3</span> The issue is of special relevance in HIV-HCV coinfected patients undergoing LT whose long-term survival has consistently been found to be shorter than that of monoinfected patients<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6-8</span></a> due to their accelerated fibrosis progression and lower response rates to interferon-based treatment.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> Hence, although prevention of recurrence holds the key to improving long-term survival, safe and effective treatment options are required for those with recurrent infection.</p><p id="p0120" class="elsevierStylePara elsevierViewall">The advent of direct acting antiviral agents (DAAs) given as interferon-free combinations has dramatically changed treatment options in the liver transplant setting. Several recent reports have shown that interferon-free DAA combinations are safe and effective for the treatment of HCV recurrence after LT.<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12,13</span></a> In this regard, SVR12 rates among LT recipients treated with the NS3 protease inhibitor simeprevir plus the NS5B polymerase inhibitor SOF, with or without ribavirin for 12 or 24 weeks, have ranged between 88 and 90%.<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12,14-16</span></a> Similarly, the combination of SOF with the NS5A inhibitor DCV with or without ribavirin for 12 or 24 weeks has also been reported to eradicate infection in 90-95% of mo-noinfected liver transplant recipients.<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12,17</span></a> Although reports using triple therapy with pegylated interferon, ribavirin and first generation protease inhibitor (bo-ceprevir or telaprevir), among HIV-HCV coinfected liver transplant recipients was shown to eradicate infection in 60% of patients,<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> poor tolerability was still a major issue. More recently, SVR rates of 90% or higher has been reported among coinfected LT recipients treated with sofosbuvir-based DAA combinations.<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">19,20</span></a> although information in this patient group remains scarce.</p><p id="p0125" class="elsevierStylePara elsevierViewall">Several findings of the current report deserve further mention. First, the majority of patients might be considered a “hard-to-treat” population with advanced, and sometimes decompensated liver disease, and prior failure to interferon-containing antiviral therapy. Yet viral suppression was remarkably fast with a mean decline in serum HCV-RNA of > 3 logs, just one-week after treatment onset. The observation that viral dynamics and SVR rates were equivalent in coinfected and HCV monoinfected patients is in accordance with the notion that, at least for genotype 1 and 4 infections, response rates to interferon-free DAA combinations are identical in mono and HIV-infected patients, as long as potential drug-drug interactions with antiretroviral agents are carefully avoided.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a></p><p id="p0130" class="elsevierStylePara elsevierViewall">Second, combination of sofosbuvir and daclatasvir was not only effective but also very well tolerated in most patients, even those with decompensated disease. The only severe adverse event was an atrioventricular block in a patient under amiodarone therapy requiring pacemaker placement. The episode occurred before a specific warning was issued regarding the risk of life-threatening bradycardia in patients under amiodarone treatment given sofosbuvir-containing DAA combina-tions.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> The fact that our patients were given a ribavirin-free DAA combination might have had an impact on tolerance and suggests that well tolerated ribavirin-free combinations for 24 weeks might have advantages over shorter RBV-containing regimens.</p><p id="p0135" class="elsevierStylePara elsevierViewall">Third, the observed virological response in our patients was associated with a remarkable improvement in liver function tests and clinical status. Dramatic clinical improvement associated with viral clearance has already been reported in HIV-coinfected LT recipients receiving sofosbuvir plus daclatasvir treatment for fibrosing cholestatic HCV recurrence.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> Indeed, recurrent ascites resolved during treatment in four of the six decompen-sated patients. However, two patients continued to have ascites and recurrent episodes of hepatic encephalopathy and eventually died with complications of end-stage liver disease despite viral eradication. This is in agreement with other reports showing that viral eradication does not necessary correlate with clinical improvement,<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">17,24,25</span></a> and strongly supports the importance of early consideration for treatment in all patients with HCV recurrence after LT.</p><p id="p0140" class="elsevierStylePara elsevierViewall">Finally, except for the patient who was receiving amio-darone, few drug-drug interactions were observed in our patients. Only two patients had biopsy-proven mild acute rejection at the end of treatment which resolved after minor dose adjustments of immunosuppressive medications. This attests for the importance of systematic and frequent monitoring of immunosuppressant drug though levels throughout treatment, since improvement in liver function may increase hepatic drug metabolism and increase the risk of acute rejection. On the other hand, although no evidence of drug-drug interaction between anti-HCV and antiretroviral medication was seen in our coinfected patients, and sofosbuvir/daclatasvir does not appear to interact with most ARV drugs,<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">26</span></a> the risk of interactions may be higher with other DAA combination and warrant close monitoring of HIV suppression.</p><p id="p0145" class="elsevierStylePara elsevierViewall">Because of its single-center observation nature and the limited number of patients included, our results have to be interpreted with caution and may not be applicable to other populations with different genotypes or more advanced disease. Furthermore, although the 20 responding patients remains clinically compensated more than one year after treatment end, the long-term clinical and histo-logical outcome of responder patients remains to be established.</p><p id="p0150" class="elsevierStylePara elsevierViewall">In conclusion, our single center experience shows that a 24-week course of SOF plus DCV without RBV, is safe and effective for LT recipients with HCV recurrence, including HIV/HCV coinfected patients without significant DDIs. These encouraging results provide hope for the improvement of long-term graft and patient survival of either HCV monoinfected or HIV coinfected LT recipients.</p></span><span id="s0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0110">Abbreviations</span><p id="p0155" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="l0010"><li class="elsevierStyleListItem" id="u0005"><span class="elsevierStyleLabel">•</span><p id="p0160" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">ART:</span> antiretroviral theraphy.</p></li><li class="elsevierStyleListItem" id="u0010"><span class="elsevierStyleLabel">•</span><p id="p0165" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">CP:</span> Child-Pugh.</p></li><li class="elsevierStyleListItem" id="u0015"><span class="elsevierStyleLabel">•</span><p id="p0170" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">Csa:</span> cyclosporine.</p></li><li class="elsevierStyleListItem" id="u0020"><span class="elsevierStyleLabel">•</span><p id="p0175" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">DAAs:</span> direct acting antiviral agents.</p></li><li class="elsevierStyleListItem" id="u0025"><span class="elsevierStyleLabel">•</span><p id="p0180" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">DCV:</span> daclatasvir.</p></li><li class="elsevierStyleListItem" id="u0030"><span class="elsevierStyleLabel">•</span><p id="p0185" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">Everol:</span> everolimus.</p></li><li class="elsevierStyleListItem" id="u0035"><span class="elsevierStyleLabel">•</span><p id="p0190" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">Fk:</span> tacrolimus.</p></li><li class="elsevierStyleListItem" id="u0040"><span class="elsevierStyleLabel">•</span><p id="p0195" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">HCV:</span> hepatitis C virus.</p></li><li class="elsevierStyleListItem" id="u0045"><span class="elsevierStyleLabel">•</span><p id="p0200" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">HIV:</span> human immunodeficiency virus.</p></li><li class="elsevierStyleListItem" id="u0050"><span class="elsevierStyleLabel">•</span><p id="p0205" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">ILB28:</span> interleukin IL28B polymorphism rs12979860.</p></li><li class="elsevierStyleListItem" id="u0055"><span class="elsevierStyleLabel">•</span><p id="p0210" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">INR:</span> International Normalized Ratio.</p></li><li class="elsevierStyleListItem" id="u0060"><span class="elsevierStyleLabel">•</span><p id="p0215" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">IQR:</span> interquartile range.</p></li><li class="elsevierStyleListItem" id="u0065"><span class="elsevierStyleLabel">•</span><p id="p0220" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">LT:</span> liver transplantation.</p></li><li class="elsevierStyleListItem" id="u0070"><span class="elsevierStyleLabel">•</span><p id="p0225" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">MELD:</span> Model for End Stage Liver Disease.</p></li><li class="elsevierStyleListItem" id="u0075"><span class="elsevierStyleLabel">•</span><p id="p0230" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">MMF:</span> mofetil mycofenolate.</p></li><li class="elsevierStyleListItem" id="u0080"><span class="elsevierStyleLabel">•</span><p id="p0235" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">Peg-IFN:</span> pegylated interferon.</p></li><li class="elsevierStyleListItem" id="u0085"><span class="elsevierStyleLabel">•</span><p id="p0240" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">PI:</span> protease inhibitor.</p></li><li class="elsevierStyleListItem" id="u0090"><span class="elsevierStyleLabel">•</span><p id="p0245" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">RBV:</span> ribavirin.</p></li><li class="elsevierStyleListItem" id="u0095"><span class="elsevierStyleLabel">•</span><p id="p0250" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">SAEs:</span> serious adverse events.</p></li><li class="elsevierStyleListItem" id="u0100"><span class="elsevierStyleLabel">•</span><p id="p0255" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">SOF:</span> sofosbuvir.</p></li><li class="elsevierStyleListItem" id="u0105"><span class="elsevierStyleLabel">•</span><p id="p0260" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">SVR:</span> sustained virological response.</p></li></ul></p></span><span id="s0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0115">Author Participation</span><p id="p0265" class="elsevierStylePara elsevierViewall">L.C, I.C-V and J.I.E. participated in making the study design, interpretation of data and writing the article; J. L; I.B; M. C; O. L; F.R-F, T.S. participated in performing the research, R.C; and R.E. critical revision of the manuscript for important intellectual content and study supervision.</p></span><span id="s0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0120">Conflict of Interest</span><p id="p0270" class="elsevierStylePara elsevierViewall">Dr Rafael Esteban has attended advisor meetings with Abbott, Boehringer Ingelheim, Bristol Myers-Squibb, Glaxo, Gilead, Janssen Merck, and Novartis; has provided lectures on behalf of Abbott, Boehringer Ingelheim, Bristol Myers-Squibb, Glaxo, Gilead, Janssen, Merck, No-vartis and Roche; and has served on a Data Safety Monitoring Board for Novartis. The authors have no other potential conflicts of interest to disclose regarding the manuscript.</p></span><span id="s0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0125">Financial Support</span><p id="p0275" class="elsevierStylePara elsevierViewall">None.</p></span><span id="s0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0130">Acknowledgements</span><p id="p0280" class="elsevierStylePara elsevierViewall">The authors thank the patients and their families. We also wish to acknowledge those at Gilead and Bristol-Myers Squibb who made the sofosbuvir and daclatasvir compassionate access program available for liver transplant patients.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres1198051" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abs0010" "titulo" => "Background and aims" ] 1 => array:2 [ "identificador" => "abs0015" "titulo" => "Material and Methods" ] 2 => array:2 [ "identificador" => "abs0020" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abs0025" "titulo" => "Conclusion" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1116695" "titulo" => "Key words" ] 2 => array:2 [ "identificador" => "s0005" "titulo" => "Introduction" ] 3 => array:3 [ "identificador" => "s0010" "titulo" => "Material and Methods" "secciones" => array:7 [ 0 => array:2 [ "identificador" => "s0015" "titulo" => "Patients" ] 1 => array:2 [ "identificador" => "s0020" "titulo" => "Study follow-up schedule" ] 2 => array:2 [ "identificador" => "s0025" "titulo" => "HCV RNA testing and genotyping" ] 3 => array:2 [ "identificador" => "s0030" "titulo" => "IL28B genotyping" ] 4 => array:2 [ "identificador" => "s0035" "titulo" => "Liver histology" ] 5 => array:2 [ "identificador" => "s0040" "titulo" => "Study assessments" ] 6 => array:2 [ "identificador" => "s0045" "titulo" => "Statistical analysis" ] ] ] 4 => array:3 [ "identificador" => "s0050" "titulo" => "Results" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "s0055" "titulo" => "Baseline characteristics" ] 1 => array:2 [ "identificador" => "s0060" "titulo" => "Efficacy" ] 2 => array:2 [ "identificador" => "s0065" "titulo" => "Liver function" ] 3 => array:2 [ "identificador" => "s0070" "titulo" => "Safety and clinical complications" ] ] ] 5 => array:2 [ "identificador" => "s0075" "titulo" => "Discussion" ] 6 => array:2 [ "identificador" => "s0080" "titulo" => "Abbreviations" ] 7 => array:2 [ "identificador" => "s0085" "titulo" => "Author Participation" ] 8 => array:2 [ "identificador" => "s0090" "titulo" => "Conflict of Interest" ] 9 => array:2 [ "identificador" => "s0095" "titulo" => "Financial Support" ] 10 => array:2 [ "identificador" => "s0100" "titulo" => "Acknowledgements" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2016-03-08" "fechaAceptado" => "2016-03-18" "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Key words" "identificador" => "xpalclavsec1116695" "palabras" => array:3 [ 0 => "Direct-acting antivirals" 1 => "Drug-drug interactions" 2 => "Liver transplant and sustained virological response" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abs0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0010">Background and aims</span><p id="sp0020" class="elsevierStyleSimplePara elsevierViewall">Pegylated interferon (Peg-INF) and ribavirin (RBV) based therapy is suboptimal and poorly tolerated. We evaluated the safety, tolerability and efficacy of a 24-week course of sofosbuvir plus daclatasvir without ribavirin for the treatment of hepatitis C virus (HCV) recurrence after liver transplantation (LT) in both HCV-monoinfected and human immunodeficiency virus (HIV)-HCV coinfected patients.</p></span> <span id="abs0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0015">Material and Methods</span><p id="sp0025" class="elsevierStyleSimplePara elsevierViewall">We retrospectively evaluated 22 consecutive adult LT recipients (16 mo-noinfected and 6 coinfected with HIV) who received a 24-week course of sofosbuvir plus daclatasvir treatment under an international compassionate access program.</p></span> <span id="abs0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0020">Results</span><p id="sp0030" class="elsevierStyleSimplePara elsevierViewall">Most patients were male (86%), with a median age of 58 years (r:58-81y). Median time from LT to treatment onset was 70 months (r: 20-116 m). HCV genotype 1b was the most frequent (45%), 55% had not responded to previous treatment with Peg-INF and RBV and 14% to regiments including first generation protease inhibitors. Fifty-six percent of the patients had histologically proven cirrhosis and 6 had ascites at baseline. All patients completed the 24-week treatment course without significant side effects except for one episode of severe bradicardya, with only minor adjustments in immunosuppressive treatment in some cases. Viral suppression was very rapid with undetectable HCV-RNA in all patients at 12 weeks. All 22 patients achieved a sustained virological response 12 weeks after treatment completion.</p></span> <span id="abs0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="st0025">Conclusion</span><p id="sp0035" class="elsevierStyleSimplePara elsevierViewall">The combination of sofosbuvir plus daclatasvir without ribavirin is a safe and effective treatment of HCV recurrence after LT in both monoinfected and HIV-coinfected patients, including those with decompensated cirrhosis.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abs0010" "titulo" => "Background and aims" ] 1 => array:2 [ "identificador" => "abs0015" "titulo" => "Material and Methods" ] 2 => array:2 [ "identificador" => "abs0020" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abs0025" "titulo" => "Conclusion" ] ] ] ] "multimedia" => array:3 [ 0 => array:7 [ "identificador" => "f0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1394 "Ancho" => 2067 "Tamanyo" => 179589 ] ] "descripcion" => array:1 [ "en" => "<p id="sp0005" class="elsevierStyleSimplePara elsevierViewall">Selected laboratory tests and scores over time. Variables are depicted as median and IQR. EOT: end of treatment. FU: follow-up. IQR: intercuarti-le range.</p>" ] ] 1 => array:8 [ "identificador" => "t0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "fuente" => "Csa: cyclosporine. Everol: everolimus. Fk: tacrolimus. IL28B: interleukin 28B. IQR: interquartile range. LT: liver transplant. MELD: Model for End Stage Liver Disease. MMF: mofetil mycofenolate. PR: pegylated interferon plus ribavirin. PI: protease inhibitor." "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Characteristics \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Overall (n = 22) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">HCV-monoinfected (n = 16) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">HCV/HIV-coinfected (n = 6) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">P-value \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Male, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">19 (86) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 (94) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (67) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Recipient age (years), median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">58 (51-68) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">65 (53-69) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">49 (43-53) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.01 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Months from LT, median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">70 (20-116) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">51 (20-125) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">84 (73-116) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.66 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hepatocelullar carcinoma, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (27) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (31) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (17) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.49 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Donor age (years), median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">58 (51-66) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">59 (53-66) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">54 (40-66) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.37 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HCV Genotype, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.16 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (22) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (19) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (33.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1a \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1b \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 (45) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8 (50) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (33.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (17) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (33.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (14) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (19) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">IL28B, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.77 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CC \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 (32) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (31) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (33) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9 (41) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (38) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (50) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">TT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (27) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (31) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (17) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Inmunosupression, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.37 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Fk monotherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 (45) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 (44) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (50) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Fk + MMF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (22) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (19) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (33) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Fk + Everol \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (18) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (25) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Csa \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Everol + MMF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No therapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (17) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">HCV-RNA (log10 IU/mL), median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.6 (6.2-6.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.6 (5.9-6.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6.4 (6.4-6.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.46 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ALT (IU/L), median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">64 (33-123) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">75 (43-132) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">42 (28-103) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.42 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Bilirubin (mg/dL), median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.2 (0.8-1.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.2 (0.7-2.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.2 (0.9-1.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.97 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Albumin (g/dL), median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.6 (3.2-4.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.4 (2.8-3.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.2 (4.2-4.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Platelets (x 10<span class="elsevierStyleSup">3</span>/mL), median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">84 (67-108) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">86 (62-111) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">84 (72-104) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.48 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Child-Pugh score, median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (5-7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (5-8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (5-5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.03 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MELD score, median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 (10-14) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 (10-14) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 (9-11) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.08 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Histology, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.86 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ishak F3-F4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (33) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (33) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (33) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ishak F5-F6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 (56) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 (59) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (50) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cholestatic hepatitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (11) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (17) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Treatment experienced; n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 (55) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 (44) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (83) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.10 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PR, \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">PR + PI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Triple therapy with PI, n (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (14) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (33) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.10 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2046069.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="sp0010" class="elsevierStyleSimplePara elsevierViewall">Baseline demographic characteristics of the entire cohort and by HIV serostatus.</p>" ] ] 2 => array:8 [ "identificador" => "t0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "fuente" => "LOQ: limit of quantification (< 15 IU/mL). LOD: limit of detection (< 10 IU/mL). SVR: sustained virological response." "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Overall (n = 22) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">HCV-monoinfected (n = 16) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">HCV/HIC-coinfected (n = 6) \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="4" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col"></th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">Week 1 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">3.3 (2.5-4.1) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">3.15 (2.35-3.55) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">4.15 (3.5-4.26) \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">Week 2 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">1.1 (0.7-1.3) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">1.1 (0.7-1.3) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">0.9 (0.3-1.3) \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">Week 3 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">0.7 (0.6-1.3) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">0.9 (0.6-1.3) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">0.6 (0.5-1.3) \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">Week 4 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">0.2 (0-0.7) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">0.2 (0-0.5) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col">0. (0-0.7) \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Week 4 HCV-RNA < LOQ \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 (50) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (37) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (83) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Week 8 HCV-RNA < LOD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">21 (95) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 (94) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (100) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Week 12 HCV-RNA < LOD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22 (100) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16 (100) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (100) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Week 24 HCV-RNA < LOD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22 (100) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16 (100) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (100) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">At week 4 (SVR4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22 (100) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16 (100) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (100) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">At week 12 (SVR12) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">22 (100) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16 (100) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (100) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2046070.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="sp0015" class="elsevierStyleSimplePara elsevierViewall">Response (HCV RNA < 15 IU/mL) during and after antiviral therapy by HIV serostatus.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bs0010" "bibliografiaReferencia" => array:26 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "for American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Ghany Mg" 1 => "Strader D.B." 2 => "Thomas D.L." 3 => "Seeff Lb" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Hepa-tology" "fecha" => "2009" "volumen" => "49" "paginaInicial" => "1335" "paginaFinal" => "1374" "itemHostRev" => array:3 [ "pii" => "S0140673617321529" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Viral hepatitis in liver transplantation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Crespo G." 1 => "Mariño Z." 2 => "Navasa M." 3 => "Forns X." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.gastro.2012.02.011" "Revista" => array:6 [ "tituloSerie" => "Gastroenterology" "fecha" => "2012" "volumen" => "142" "paginaInicial" => "1373" "paginaFinal" => "1383" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22537446" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Berenguer M." 1 => "Schuppan D." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2012.12.014" "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "2013" "volumen" => "58" "paginaInicial" => "1028" "paginaFinal" => "1041" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23262248" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantat" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Berenguer M." 1 => "Palau A." 2 => "Aguilera V." 3 => "Rayón J.M." 4 => "Juan F.S." 5 => "Prieto M." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Am J Transpl" "fecha" => "2008" "volumen" => "8" "paginaInicial" => "679" "paginaFinal" => "687" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pegylated interferon plus riba-virin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Castells L." 1 => "Rimola A." 2 => "Manzardo C." 3 => "Valdivieso A." 4 => "Montero J.L." 5 => "Barcena R." 6 => "Abradelo M." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2014.07.034" "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "2015" "volumen" => "62" "paginaInicial" => "92" "paginaFinal" => "100" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25127748" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Duclos-Vallée J.C." 1 => "Féray C." 2 => "Sebagh M." 3 => "Teicher E." 4 => "Roque-Afonso A.M." 5 => "Roche B." 6 => "Azoulay D." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.21990" "Revista" => array:6 [ "tituloSerie" => "Hepatology" "fecha" => "2008" "volumen" => "47" "paginaInicial" => "407" "paginaFinal" => "417" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18098295" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Outcome of HCV/HIV-coinfected liver transplant recipients: A prospective and multicenter cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Miró J.M." 1 => "Montejo M." 2 => "Castells L." 3 => "Rafecas A." 4 => "Moreno S." 5 => "Agüe-ro F." 6 => "Abradelo M." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Am J Tranplant" "fecha" => "2012" "volumen" => "12" "paginaInicial" => "1866" "paginaFinal" => "1876" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Terrault N.A." 1 => "Roland M.E." 2 => "Schiano T." 3 => "Dove L." 4 => "Wong M.T." 5 => "Poor-dad F." 6 => "Ragni M.V." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/lt.23411" "Revista" => array:6 [ "tituloSerie" => "Liver Transpl" "fecha" => "2012" "volumen" => "18" "paginaInicial" => "716" "paginaFinal" => "726" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22328294" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "McCarthy J.J." 1 => "Li J.H." 2 => "Thompson A." 3 => "Suchindran S." 4 => "Lao X.Q." 5 => "Pa-tel K." 6 => "Tillmann H.L." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.gastro.2010.02.009" "Revista" => array:6 [ "tituloSerie" => "Gastroenterology" "fecha" => "2010" "volumen" => "138" "paginaInicial" => "2307" "paginaFinal" => "2314" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20176026" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Montes-Cano M.A." 1 => "García-Lozano J.R." 2 => "Abad-Molina C." 3 => "Romero-Gómez M." 4 => "Barroso N." 5 => "Aguilar-Reina J." 6 => "Núñez-Roldán A." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.23624" "Revista" => array:7 [ "tituloSerie" => "Hepatology" "fecha" => "2010" "volumen" => "52" "paginaInicial" => "33" "paginaFinal" => "37" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20578254" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1473309917303018" "estado" => "S300" "issn" => "14733099" ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Histological grading and staging of chronic hepatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Ishak K." 1 => "Baptista A." 2 => "Bianchi L." 3 => "Callea F." 4 => "De Groote J." 5 => "Gudat F." 6 => "Denk H." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "J Hepatol" "fecha" => "1995" "volumen" => "22" "paginaInicial" => "696" "paginaFinal" => "699" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7560864" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1474442217302995" "estado" => "S300" "issn" => "14744422" ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real world experience from the hepatitis C therapeutic registry and research network" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Brown R.S." 1 => "O’Leary J.G." 2 => "Reddy K.R." 3 => "Kuo A." 4 => "Morelli G.J." 5 => "Burton J.R. Jr" 6 => "Stravitz R.T." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/lt.24366" "Revista" => array:6 [ "tituloSerie" => "Liver Transpl" "fecha" => "2016" "volumen" => "22" "paginaInicial" => "24" "paginaFinal" => "33" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26519873" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Daclatasvir with sofosbuvir and rib-avirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Poordad F." 1 => "Schiff E.R." 2 => "Vierling J.M." 3 => "Landis C." 4 => "Fontana R.J." 5 => "Yang R." 6 => "McPhee F." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:2 [ "titulo" => "Hepatology" "serieFecha" => "2016" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Pungpanpong S." 1 => "Acqel B." 2 => "Leise M." 3 => "Werner K.T." 4 => "Murphy J.L." 5 => "Henry T.M." 6 => "Ryland K." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.27770" "Revista" => array:7 [ "tituloSerie" => "Hepatology" "fecha" => "2015" "volumen" => "61" "paginaInicial" => "1880" "paginaFinal" => "1886" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25722203" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1474442218303879" "estado" => "S300" "issn" => "14744422" ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Saab S." 1 => "Greenberg A." 2 => "Li E." 3 => "Bau S.N." 4 => "Durazo F." 5 => "El-Kabany M." 6 => "Han S." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/liv.12856" "Revista" => array:6 [ "tituloSerie" => "Liver Int" "fecha" => "2015" "volumen" => "35" "paginaInicial" => "2442" "paginaFinal" => "2447" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25913321" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sofosbuvir and simeprevir for treatment of hepatitis c virus infection in liver transplant recipients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Gutierrez J.A." 1 => "Carrion A.F." 2 => "Avalos D." 3 => "O’Brien C." 4 => "Martin P." 5 => "Bha-midimarri K.R." 6 => "Peyton A." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/lt.24126" "Revista" => array:6 [ "tituloSerie" => "Liver Transpl" "fecha" => "2015" "volumen" => "21" "paginaInicial" => "823" "paginaFinal" => "830" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25825070" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Pellicelli A.M." 1 => "Montalbano M." 2 => "Lionetti R." 3 => "Durand C." 4 => "Ferenci P." 5 => "D’Offizi G." 6 => "Knop V." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Sem Liv Dis" "fecha" => "2014" "volumen" => "46" "paginaInicial" => "923" "paginaFinal" => "927" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Therapy with boceprevir or telaprevir in HIV/hepatitic C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Antonini T.M." 1 => "Furlan V." 2 => "Teicher E." 3 => "Haim-Boukobza S." 4 => "Sebagh M." 5 => "Coilly A." 6 => "Bonhomme-Faivre L." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAD.0000000000000516" "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2015" "volumen" => "29" "paginaInicial" => "53" "paginaFinal" => "58" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25387314" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sofosbuvir, simeprevir plus ribavirin for treatment of HCV recurrent in HIV-HCV coinfected liver transplant recipients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Campos-Varela I." 1 => "Stralery S." 2 => "Agudelo E.Z" 3 => "Carlson L." 4 => "Ter-rault N.A." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/lt.24027" "Revista" => array:6 [ "tituloSerie" => "Liver Transpl" "fecha" => "2015" "volumen" => "21" "paginaInicial" => "272" "paginaFinal" => "274" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25332190" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Succesful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Grant J.L." 1 => "Hawkins C." 2 => "Brooks H." 3 => "Palella F.J. Jr" 4 => "Koppe S.W." 5 => "Abecassis M.M." 6 => "Stosor V." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAD.0000000000000887" "Revista" => array:7 [ "tituloSerie" => "AIDS" "fecha" => "2016" "volumen" => "30" "paginaInicial" => "93" "paginaFinal" => "98" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26731756" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1474442213703107" "estado" => "S300" "issn" => "14744422" ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "HIV coinfected have similar SVR rates as HCV monoinfected with DAAs: It’s Time to End Segregation and Integrate HIV patients into HCV trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Shafran S.D." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/cid/civ438" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2015" "volumen" => "61" "paginaInicial" => "1127" "paginaFinal" => "1134" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26060286" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Anonymous. FDA warns of serious slowing of the heart rate when the antiarrythmic drug amiodarone is used with hepatitis C treatments containig sofosbuvir (Harvoni) or Sovaldi in combination with another Direct Acting Antiviral drug. Available from: WWW.fda.gov: accessed May 17, 2015" ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of sofosbuvir and da-clatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Leroy V." 1 => "Dumortier J." 2 => "Coilly A." 3 => "Sebagh M." 4 => "Fougerou-Leurent C." 5 => "Radenne S." 6 => "Botta D." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cgh.2015.05.030" "Revista" => array:6 [ "tituloSerie" => "Clin Gastroenterol Hepatol" "fecha" => "2015" "volumen" => "13" "paginaInicial" => "1993" "paginaFinal" => "2001" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26044317" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "News challenges in the treatment of hepatitis C in liver transplantation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Coilly A." 1 => "Roche B." 2 => "Duclos-Vallée J.C." 3 => "Samuel D." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/liv.13017" "Revista" => array:7 [ "tituloSerie" => "Liver Int" "fecha" => "2016" "volumen" => "36" "numero" => "Suppl.1" "paginaInicial" => "34" "paginaFinal" => "42" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26725895" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Timing for treatment of HCV recurrence after liver transplantation: the earlier the better" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Russo F.P." 1 => "Zanetto A." 2 => "Burra P." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:2 [ "titulo" => "Transpl Int" "serieFecha" => "2011" ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Advances in therapy for HIV/hepatitis C vírus-coinfected patients in the liver transplant setting" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Campos Varela I." 1 => "Peters M.G." 2 => "Terrault N." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/cid/ciu731" "Revista" => array:7 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2015" "volumen" => "60" "paginaInicial" => "108" "paginaFinal" => "116" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25228702" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1474442210701824" "estado" => "S300" "issn" => "14744422" ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/16652681/0000001600000001/v1_201905311015/S1665268119303655/v1_201905311015/en/main.assets" "Apartado" => array:4 [ "identificador" => "77721" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original Article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/16652681/0000001600000001/v1_201905311015/S1665268119303655/v1_201905311015/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119303655?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 6 | 0 | 6 |
| 2024 October | 16 | 5 | 21 |
| 2024 September | 13 | 4 | 17 |
| 2024 August | 20 | 6 | 26 |
| 2024 July | 18 | 4 | 22 |
| 2024 June | 13 | 2 | 15 |
| 2024 May | 7 | 3 | 10 |
| 2024 April | 23 | 3 | 26 |
| 2024 March | 16 | 1 | 17 |
| 2024 February | 13 | 5 | 18 |
| 2024 January | 13 | 8 | 21 |
| 2023 December | 23 | 3 | 26 |
| 2023 November | 25 | 4 | 29 |
| 2023 October | 20 | 7 | 27 |
| 2023 September | 8 | 0 | 8 |
| 2023 August | 11 | 2 | 13 |
| 2023 July | 9 | 6 | 15 |
| 2023 June | 9 | 5 | 14 |
| 2023 May | 12 | 7 | 19 |
| 2023 April | 5 | 1 | 6 |
| 2023 March | 11 | 5 | 16 |
| 2023 February | 15 | 1 | 16 |
| 2023 January | 8 | 2 | 10 |
| 2022 December | 12 | 6 | 18 |
| 2022 November | 19 | 4 | 23 |
| 2022 October | 11 | 6 | 17 |
| 2022 September | 13 | 8 | 21 |
| 2022 August | 8 | 5 | 13 |
| 2022 July | 11 | 9 | 20 |
| 2022 June | 10 | 7 | 17 |
| 2022 May | 18 | 6 | 24 |
| 2022 April | 10 | 7 | 17 |
| 2022 March | 12 | 5 | 17 |
| 2022 February | 7 | 5 | 12 |
| 2022 January | 14 | 8 | 22 |
| 2021 December | 9 | 7 | 16 |
| 2021 November | 10 | 5 | 15 |
| 2021 October | 17 | 13 | 30 |
| 2021 September | 6 | 9 | 15 |
| 2021 August | 7 | 6 | 13 |
| 2021 July | 7 | 6 | 13 |
| 2021 June | 11 | 11 | 22 |
| 2021 May | 11 | 6 | 17 |
| 2021 April | 41 | 17 | 58 |
| 2021 March | 8 | 5 | 13 |
| 2021 February | 9 | 7 | 16 |
| 2021 January | 4 | 9 | 13 |
| 2020 December | 6 | 10 | 16 |
| 2020 November | 7 | 7 | 14 |
| 2020 October | 4 | 4 | 8 |
| 2020 September | 8 | 7 | 15 |
| 2020 August | 5 | 7 | 12 |
| 2020 July | 7 | 8 | 15 |
| 2020 June | 5 | 7 | 12 |
| 2020 May | 3 | 6 | 9 |
| 2020 April | 3 | 3 | 6 |
| 2020 March | 2 | 3 | 5 |
| 2020 February | 6 | 5 | 11 |
| 2020 January | 5 | 3 | 8 |
| 2019 December | 6 | 9 | 15 |
| 2019 November | 2 | 2 | 4 |
| 2019 October | 7 | 1 | 8 |
| 2019 September | 2 | 2 | 4 |
| 2019 August | 2 | 1 | 3 |
| 2019 July | 4 | 9 | 13 |
| 2019 June | 14 | 6 | 20 |
| 2019 May | 2 | 4 | 6 |
Show all
